JPMorgan initiated coverage of U.S. Physical Therapy with an Overweight rating and $108 price target. The analyst believes the company should benefit from secular tailwinds including demographic trends and a growing focus on cost, quality, and outcomes. Solid long-term organic growth drivers, including an aging population, will be supplemented by continued accretive capital deployment, the analyst tells investors in a research note.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on USPH:
- U.S. Physical Therapy upgraded to Outperform from Market Perform at CJS Securities
- U.S. Physical Therapy price target raised to $124 from $116 at Barrington
- U.S. Physical Therapy reports Q2 EPS 64c, consensus 75c
- U.S. Physical Therapy acquires 70% stake in five clinic practice for $2.1M
- USPH Earnings Report this Week: Is It a Buy, Ahead of Earnings?
